Anthracyclines
Showing 1 - 25 of 417
Breast Cancer, Lymphoma, Large B-Cell, Diffuse, Cardiotoxicity Trial in Rozzano (Nebivolol, Placebo)
Active, not recruiting
- Breast Cancer
- +4 more
- Nebivolol
- Placebo
-
Rozzano, Milan, ItalyIRCCS Humanitas Research Hospital
Feb 5, 2023
Myocardial Function by Speckle Tracking After Cancer Treatment
Completed
- Myocardial Function
- +2 more
- Speckle Tracking Echocardiography
-
Montpellier, FranceUniversity Hospital of Montpellier
Feb 25, 2022
Breast Cancer Trial in Brazil (Docetaxel or Paclitaxel, Cyclophosphamide + Doxorrubicin)
Recruiting
- Breast Cancer
- Docetaxel or Paclitaxel
- Cyclophosphamide + Doxorrubicin
-
Goiânia, Goiás, Brazil
- +9 more
Jan 5, 2023
Cardiotoxicity Trial in Warsaw (Empagliflozin 10 MG, Placebo)
Not yet recruiting
- Cardiotoxicity
- Empagliflozin 10 MG
- Placebo
-
Warsaw, Poland
- +1 more
Mar 5, 2022
Breast Cancer, Cardiotoxicity Trial in Florence (Bisoprolol, Ramipril, Placebo)
Active, not recruiting
- Breast Cancer
- Cardiotoxicity
- Bisoprolol
- +2 more
-
Florence, ItalyAzienda Ospedaliero-Universitaria Careggi, Florence University
Jan 16, 2022
Anthracycline-induced Cardiac Toxicity, Non-Hodgkin Lymphoma Trial in Worldwide (RIPC, Simulated RIPC (Sham))
Recruiting
- Anthracycline-induced Cardiac Toxicity
- Non-Hodgkin Lymphoma
- RIPC
- Simulated RIPC (Sham)
-
Aarhus, Denmark
- +18 more
Oct 5, 2022
Anlotinib Combined With Chemotherapy for Treatment of HER2
Not yet recruiting
- HER2-negative Breast Cancer
- (no location specified)
Apr 18, 2022
Heart Failure Trial in Boston, Philadelphia, Toronto (Placebo, Atorvastatin)
Active, not recruiting
- Heart Failure
- Placebo
- Atorvastatin
-
Boston, Massachusetts
- +3 more
Oct 13, 2021
Cardiotoxicity, Toxicity Due to Chemo, Breast Cancer Trial in Duarte, Philadelphia, West Chester (Biomarker Guided Intervention)
Recruiting
- Cardiotoxicity
- +5 more
- Biomarker Guided Intervention
-
Duarte, California
- +2 more
Jul 29, 2022
Breast Cancer, Metastatic Breast Cancer, Cancer Therapy-Related Cardiac Dysfunction Trial in Lørenskog (Nicotinamide Riboside,
Not yet recruiting
- Breast Cancer
- +4 more
- Nicotinamide Riboside
- Placebo
-
Lørenskog, Akershus, NorwayAkershus University Hospital
Feb 14, 2023
Cardiomyopathy, Heart Failure Trial in Houston (Laboratory Biomarker Analysis, Standard of Care, Mesenchymal Stem Cell
Completed
- Cardiomyopathy
- Heart Failure
- Laboratory Biomarker Analysis
- +2 more
-
Houston, TexasM D Anderson Cancer Center
May 11, 2022
Cancer Related Cardiovascular Toxicity Trial in Italy, North Macedonia, Serbia (Prospective validation of the HFA-ICOS risk
Not yet recruiting
- Cancer Related Cardiovascular Toxicity
- Prospective validation of the HFA-ICOS risk score in a subset of subjects with newly diagnosed breast cancer and undergoing treatment with anthracyclines analogues with or without radiotherapy
-
Bologna, Italy
- +4 more
Oct 11, 2023
HER2-negative Breast Cancer, Neoadjuvant Therapy, Pathological Complete Response Trial in Beijing (Camrelizumab with vinorelbine
Recruiting
- HER2-negative Breast Cancer
- +5 more
- Camrelizumab with vinorelbine and cisplatin
-
Beijing, Beijing, ChinaPeking University First Hospital
Oct 15, 2022
Breast Cancer Trial in Strasbourg (Microbiopsy sample, Muscle echography, Maximal strength, Body composition, Quality of life
Completed
- Breast Cancer
- Microbiopsy sample
- Muscle echography, Maximal strength, Body composition, Quality of life and Physical activity level
-
Strasbourg, FranceInstitut de Cancerologie Strasbourg Europe
Jun 7, 2021
Triple-negative Breast Cancer Trial in China (Chiauranib, capecitabine)
Recruiting
- Triple-negative Breast Cancer
-
Guangzhou, Guangdong, China
- +3 more
Apr 14, 2022
Cardiotoxicity of Anthracyclines in Diffuse Large B-Cell
Active, not recruiting
- Lymphoma
- +2 more
- R-CHOP with doxorubicin
-
Messina, ME, Italy
- +17 more
Apr 22, 2022
Breast Cancer Trial in Lyon, Saint-herblain (Combination of ribociclib + capecitabine)
Active, not recruiting
- Breast Cancer
- Combination of ribociclib + capecitabine
-
Lyon, France
- +1 more
Mar 8, 2022
Cardiotoxicity, Cardiac Rehabilitation Trial in Santiago de Compostela (Cardiac rehabilitation)
Active, not recruiting
- Cardiotoxicity
- Cardiac Rehabilitation
- Cardiac rehabilitation
-
Santiago de Compostela, A Coruña, SpainHospital Clínico Universitario de Santiago
May 8, 2021
Cardiotoxicity, Cardiovascular Disease, Neurovascular Disorder Trial in Sao Paulo (procedure, diagnostic test, drug)
Recruiting
- Cardiotoxicity
- +4 more
- Physical Characteristics
- +10 more
-
Sao Paulo, BrazilInstituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Fac
Sep 28, 2021
Cancer Treatment
Recruiting
- Toxicity Due to Chemotherapy
- +2 more
- Anthracyclines
- +3 more
-
Groningen, NetherlandsUniversity Medical Center Groningen
Feb 1, 2021
Metastatic Ovarian Cancer, Triple Negative Breast Cancer Trial in Re?ovot (Nerofe is a first in class derivative of a human
Withdrawn
- Metastatic Ovarian Cancer
- Triple Negative Breast Cancer
- Nerofe is a first in class derivative of a human hormon-peptide(TCApF), with Cancer suppressive properties.
-
Reẖovot, IsraelOncologic Institue, Kaplan
Oct 18, 2021
Breast Cancer Female, Adriamycin Toxicity Trial in Baltimore (10,000 steps, Usual Care)
Completed
- Breast Cancer Female
- Adriamycin Toxicity
- 10,000 steps
- Usual Care
-
Baltimore, MarylandJohns Hopkins Hospital
Dec 31, 2020
Metastatic Breast Cancer Trial in France (AZD2014, AZD4547, AZD5363)
Active, not recruiting
- Metastatic Breast Cancer
- AZD2014
- +18 more
-
Angers, France
- +24 more
Mar 8, 2022
Breast Cancer Trial in Xi'an (nab-paclitaxel followed by anthracycline and cyclophosphamide, Docetaxel followed by anthracycline
Unknown status
- Breast Cancer
- nab-paclitaxel followed by anthracycline and cyclophosphamide
- Docetaxel followed by anthracycline and cyclophosphamide
-
Xi'an, Shaanxi, ChinaXijing hospital
Nov 27, 2019